{"filing":{"accession_number":"0001140361-26-024407","cik":"0000874015","ticker":"IONS","company_name":"IONIS PHARMACEUTICALS INC","form":"8-K","filing_date":"2026-06-08","report_date":null,"primary_document":"ef20075669_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/874015/000114036126024407/ef20075669_8k.htm"},"events":[{"id":6158,"run_id":5407,"accession_number":"0001140361-26-024407","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Ludwig N. Hantson was appointed to the Board of Directors of Ionis Pharmaceuticals effective June 4, 2026. Hantson brings 30+ years of biopharmaceutical leadership experience, including prior CEO roles at Alexion and Baxalta.","company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","filing_date":"2026-06-08","form":"8-K","submitted_at":null,"items":[{"id":5121,"accession_number":"0001140361-26-024407","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Ludwig N. Hantson to the Board of Directors of Ionis Pharmaceuticals effective June 4, 2026. The principal action is a person taking a board role, with detailed background on his 30+ years of biopharmaceutical leadership experience including prior CEO roles at Alexion and Baxalta. Board appointments are material events affecting corporate governance and investor assessment of the company's leadership.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T16:51:10.836181+00:00","company_name":"","ticker":null,"filing_date":""},{"id":5122,"accession_number":"0001140361-26-024407","item_number":"7.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses that Dr. Hantson was appointed to the Company's Board on June 4, 2026, with the announcement made via press release on June 8, 2026. Board appointments are material events affecting the composition of the registrant's governance and are typically disclosed under Item 5.02; disclosure here under Item 7.01 (Regulation FD) does not change the underlying event classification. This is a clear executive appointment event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T16:51:10.836181+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":6159,"run_id":5407,"accession_number":"0001140361-26-024407","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Ionis Pharmaceuticals held its Annual Meeting of Stockholders on June 4, 2026, with voting results disclosed for five proposals: director elections (Berthelsen and Herman), advisory compensation vote, equity plan amendment (9.5M shares), employee stock purchase plan amendment, and auditor ratification.","company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","filing_date":"2026-06-08","form":"8-K","submitted_at":null,"items":[{"id":5123,"accession_number":"0001140361-26-024407","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 discloses the results of Ionis Pharmaceuticals' Annual Meeting of Stockholders held on June 4, 2026, with detailed voting tallies for five proposals: director elections (Berthelsen and Herman), advisory compensation vote, equity plan amendment (9.5M shares), employee stock purchase plan amendment, and auditor ratification. The disclosure of shareholder vote results is a core Item 5.07 event and is material to investors as it confirms governance actions and capital allocation decisions.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T16:51:10.836181+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5121,"accession_number":"0001140361-26-024407","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Ludwig N. Hantson to the Board of Directors of Ionis Pharmaceuticals effective June 4, 2026. The principal action is a person taking a board role, with detailed background on his 30+ years of biopharmaceutical leadership experience including prior CEO roles at Alexion and Baxalta. Board appointments are material events affecting corporate governance and investor assessment of the company's leadership.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T16:51:10.836181+00:00","company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","filing_date":"2026-06-08"},{"id":5122,"accession_number":"0001140361-26-024407","item_number":"7.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses that Dr. Hantson was appointed to the Company's Board on June 4, 2026, with the announcement made via press release on June 8, 2026. Board appointments are material events affecting the composition of the registrant's governance and are typically disclosed under Item 5.02; disclosure here under Item 7.01 (Regulation FD) does not change the underlying event classification. This is a clear executive appointment event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T16:51:10.836181+00:00","company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","filing_date":"2026-06-08"},{"id":5123,"accession_number":"0001140361-26-024407","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 discloses the results of Ionis Pharmaceuticals' Annual Meeting of Stockholders held on June 4, 2026, with detailed voting tallies for five proposals: director elections (Berthelsen and Herman), advisory compensation vote, equity plan amendment (9.5M shares), employee stock purchase plan amendment, and auditor ratification. The disclosure of shareholder vote results is a core Item 5.07 event and is material to investors as it confirms governance actions and capital allocation decisions.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T16:51:10.836181+00:00","company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","filing_date":"2026-06-08"}]}